Markus Wendling

Dr. Markus Wendling


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
BSBo Sterckx
Bo Sterckx
ISIsabell Steinseifer
Isabell Steinseifer
MWMarkus Wendling
Markus Wendling
Electronic portal imaging device-based in vivo dosimetry with a commercial product was performed for 10 prostate cancer patients treated with an air-filled endorectal balloon. With the conventional in vivo method the verification results were outside of our clinical acceptance criteria for all patients. The in aqua vivo method, originally developed for lung cancer treatments, proved to be a practical solution to this problem. On average the percentage of points within γ agreement of 3% and 3 mm significantly improved from 90.9% ± 2.5% (1SD) for the conventional in vivo method to 99.0% ± 1.0% (1SD) for the in aqua vivo method.

22 August 2021 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
MCMaurice C. Cox
Maurice C. Cox
PBPètra M. Braam
Pètra M. Braam
HRHeidi Rutten
Heidi Rutten
RLRuud van Leeuwen
Ruud van Leeuwen
MWMarkus Wendling
Markus Wendling
In rectal cancer patients, radiotherapy in prone position using a belly board can reduce the dose to organs at risk. For this patient group we investigated inter-fraction shape variation of the mesorectal part of the clinical target volume (CTV) and determined planning target volume (PTV) margins. Patients with rectal cancer receiving neoadjuvant (chemo)radiotherapy were eligible. For each patient a planning computed tomography (pCT) and five cone-beam CT (CBCT) scans were acquired in prone position using a belly board. The mesorectal CTV was delineated on all scans. Mesorectal shape variation was quantified relative to the pCT. PTV margins were derived locally and averaged for separate subregions of the mesorectal CTV. For each patient a total PTV was constructed using our clinical margins for mesorectal and lymph node CTVs. An artificial dose distribution conforming to this PTV was used to calculate the coverage for the mesorectal CTV using the CBCT delineations. In 19 rectal cancer patients the derived PTV margins were smallest in the upper-lateral region (6 mm) and largest in the upper-anterior region (16 mm). PTV margins for the upper-anterior region were larger for female patients (19 mm) compared to male patients (14 mm). Clinical margins for the total PTV were sufficient for a coverage of at least 97% of the mesorectal CTV for all patients. Mesorectal shape variation is heterogeneous and largest in the upper-anterior region, in rectal cancer patients irradiated in prone position and using a belly board.